mots-c vs ss-31
mots-c (B-tier) vs ss-31 (A-tier). mechanism, trials, evidence boundaries, dosing literature. side-by-side reference.
mots-c · tier B
mitochondrial peptide your body makes during exercise. restores metabolic health in mice. never given to a person in a trial.
a mitochondrial-derived peptide. AMPK activation, mouse data is strong and replicated. no trial has ever given it to a person, and the one registry record saying otherwise is fabricated.
16 aa mitochondrial-derived · half-life minutes in plasma; functional effects persist hours via downstream gene expression · focus
ss-31 · tier A
the first mitochondria-targeted peptide drug. FDA-approved september 2025. for Barth syndrome, studied for heart failure.
the first FDA-approved peptide drug that targets mitochondria. Forzinity for Barth syndrome, ~$800,000 a year.
FDA '25 elamipretide · Barth syndrome · half-life 3-4 hours in circulation; functional effects persist 12-16 hours due to mitochondrial retention · healing
at a glance
reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.